SEC Form 4 · accession 0001213900-26-093698
Estrella Immunopharma, Inc. · ESLA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jiandong Xu
Officer — Chief Financial Officer
Period of report
Aug 18, 2026
Accepted (ET)
Aug 25, 2026 · 9:55 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001844417
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock, par value $0.0001 per shareF1,F2 | Aug 18, 2026 | M | 100,000 | $0.815 | A | 365,488 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Incentive Share OptionF3,F4 | $0.815 | Aug 18, 2026 | M | 100,000 | D | Oct 31, 2024 | Oct 29, 2034 | Common Stock | 100,000 | 390,796 | D |
Explanation of responses
- F1Represents the exercise price per share paid by the Reporting Person upon the exercise of the stock options reported in Table II.
- F2Reflects the 265,488 shares of Common Stock directly beneficially owned as reported on the Reporting Person's most recent Form 4, plus the 100,000 shares acquired upon the reported exercise.
- F3Represents incentive share options granted to the Reporting Person on October 30, 2024 under the Issuer's 2023 Omnibus Incentive Plan, of which twenty-five percent (25%) was immediately exercisable on the date of grant, with the remainder vesting in equal monthly installments of 1/48th of the total award on each monthly anniversary of October 30, 2024. The options were vested as to the shares exercised.
- F4Not applicable - the reported transaction is the exercise of the stock option for the exercise price set forth in Column 2; no separate consideration was paid or received for the derivative security.